Fluvastatin is indicated for the following cases-

• Hyperlipidemia
• Prevention of Cardiovascular diseases (myocardial infarction, stroke, angina etc.)
• Coronary heart diseases

Hyperlipidemia

Prevention of Cardiovascular diseases

Coronary Heart Disease

Adults: The recommended starting dose for FLUVASTATIN is one 40 mg capsule in the evening, or one FLUVASTATIN 40 mg capsule twice daily. Do not take two FLUVASTATIN 40 mg capsules at one time. The recommended starting dose for FLUVASTATIN is one 80 mg tablet administered as a single dose at any time of the day.

Pediatric Patients: The recommended starting dose is one 20 mg FLUVASTATIN capsule. Dose adjustments, up to a maximum daily dose administered either as FLUVASTATIN capsules 40 mg twice daily or one FLUVASTATIN 80 mg tablet once daily should be made at 6 week intervals. Doses should be individualized according to the goal of therapy.

Use with Cyclosporin and Fluconazole: The dose of FLUVASTATIN should not exceed 40 mg ( or 20 mg 2x a day) when co administered with mentioned drugs.

Side effects associated with FLUVASTATIN is usually mild and transient. The most commonly reported adverse reactions in patients treated with FLUVASTATIN include-

• nasopharyngitis 
• arthralgia/ myalgia 
• diarrhea 
• pain in extremity 
• urinary tract infection 

Nasopharyngitis

Myalgia

Diarrhea

UTI (Urinary Tract Infection)

• Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with FLUVASTATIN and with other drugs in this class. A history of renal impairment may be a risk factor for the development of rhabdomyolysis. Such patients merit closer monitoring for skeletal muscle effects.
• The risk of myopathy during treatment with drugs in this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, combination of ritonavir plus saquinavir or lopinavir plus ritonavir, niacin, or azole antifungals.
• Physicians considering combined therapy with FLUVASTATIN and fibric acid derivatives, erythromycin, clarithromycin, a combination of ritonavir plus saquinavir or lopinavir plus ritonavir, immunosuppressive drugs, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. Lower starting and maintenance doses of FLUVASTATIN should be considered when taken concomitantly with the aforementioned drugs.